[Activity Report] The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery releases recommendations entitled, “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.” (August 2, 2022)
date : 11/2/2022
Tags: AMR
The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery, for which AMR Alliance Japan (Secretariat: HGPI) is a cooperating member, has released recommendations on “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.”
The recommendation can be found here.
*Available Only in Japanese
■The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery
The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery is comprised of The Japanese Society of Chemotherapy, The Japanese Association for Infectious Disease, The Japanese Society for Clinical Microbiology, The Japanese Society for Infection Prevention and Control, The Japanese Society for Bacteriology, The Pharmaceutical Society of Japan, and The Japanese Society of Veterinary Science. It investigates the promotion of infectious disease therapy and drug therapy from a medical perspective.
■AMR Alliance Japan
AMR Alliance Japan AMR was established in November 2018 as a multi-stakeholder, collaborative organization dedicated to the improvement of public health through the promotion of AMR countermeasures. As of August 2022, its members include MSD K.K., “Kodomo to Iryo” Project, Shionogi & Co., Ltd., Sumitomo-Pharma Co., Ltd., The Japanese Society of Antimicrobials for Animals, NISSUI Pharmaceutical Co., Ltd., Nippon Becton Dickson Co., Ltd., The Japan Medical Association, The Japanese Society for Medical Mycology, The Japanese Society of Pharmaceutical Health Care and Sciences, The Japanese Society of Chemotherapy, The Japanese Society for Infection Prevention and Control, The Japanese Association for Infectious Diseases, The Japanese Society for Pediatric Infectious Diseases, The Japan Pharmaceutical Manufacturers Association, The Japanese Society of Therapeutic Drug Monitoring, The Japanese Society of Hospital Pharmacists, The Pharmaceutical Society of Japan; The Japan Pharmaceutical Association, The Japanese Society for Clinical Microbiology, bioMérieux Japan Ltd., Himeji City, Pfizer Japan Inc., and Meiji Seika Pharma Co., Ltd. The Health and Global Policy Institute serves as the Secretariat of AMR Alliance Japan.
Top Research & Recommendations Posts
- [Policy Recommendations] Joint Statement “Protecting the Health of Both the Planet and People — A Japan-Model Planetary Health Strategy to Turn the Climate Crisis into an Opportunity for Health, the Economy, and Growth” (June 24, 2026)
- [Policy Recommendations] Improving Patient Access to Genomic Cancer Medicine (August 10, 2023)
- [Research Report] Perceptions, Knowledge, Actions and Perspectives of Healthcare Organizations in Japan in Relation to Climate Change and Health: A Cross-Sectional Study (November 13, 2025)
- [Research Report] Energy Conservation and Greenhouse Gas Emissions Reduction in Healthcare Facilities: Case Studies from New Construction and Facility Renewal (March 16, 2026)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] AMR Policy Update #6: The New Global Action Plan on AMR (Part 1)
- [Recommendations] Strengthening Epidemiology Education in the Veterinary Field for the One Health Era (June 19, 2026)
- [Policy Recommendations] Reshaping Japan’s Immunization Policy for Life Course Coverage and Vaccine Equity: Challenges and Prospects for an Era of Prevention and Health Promotion (April 25, 2025)
- [Public Comment Submission] “The 7th Science, Technology and Innovation Basic Plan” (Draft) (February 19, 2026)
- [Policy Recommendations] Mental Health Project: Recommendations on Three Issues in the Area of Mental Health (July 4, 2025)
Featured Posts
-
2026-06-04
[Registration Open] (Webinar) The 3rd J-PEP Seminar “Social Participation of People with Intractable Diseases and the Potential of a New Way of Working — ‘RD Workers’ — Lessons from Policy Advocacy Practice” (July 22, 2026)
-
2026-06-15
[Registration Open] (Hybrid Format) Multidisciplinary Symposium for Cardiology, Nephrology, and Metabolic Medicine “Future Actions for Making Full Use of the Health Checkup System: Connecting Checkups to Treatment From the Perspective of Data Linkage” (July 6, 2026)
-
2026-06-19
[Recommendations] Strengthening Epidemiology Education in the Veterinary Field for the One Health Era (June 19, 2026)
-
2026-06-24
[Policy Recommendations] Joint Statement “Protecting the Health of Both the Planet and People — A Japan-Model Planetary Health Strategy to Turn the Climate Crisis into an Opportunity for Health, the Economy, and Growth” (June 24, 2026)
-
2026-07-02
[Research Report] Medical Practitioner Interviews on the Current State and Issues for Interdepartmental Collaboration in Clinical Practice for Chronic Kidney Disease (June 30, 2026)



